CLOUDR(09955) released its annual performance, with revenue of 1.623 billion yuan and a gross profit of 775 million yuan.

CLOUDR (09955) announced its annual performance for the year ending December 31, 2025, with revenue of 1.623 billion RMB (yuan, same below); gross profit of 775 million RMB; and gross profit margin of 47.8%. The announcement stated that the significant increase in overall gross profit margin was due to the optimization of revenue structure, focusing on high-profit subscription solutions and P2M solutions in both in-hospital and out-hospital settings. In-hospital solutions. The gross profit margin of in-hospital solutions increased significantly from 25.2% in the year ending December 31, 2024, to 48.0% in the year ending December 31, 2025, mainly attributed to the increase in revenue contribution from high-profit subscription solutions (i.e., precision marketing services provided to pharmaceutical companies) and self-operated SKU P2M solutions due to business restructuring. Out-hospital solutions. The gross profit margin of out-hospital solutions increased significantly from 23.1% in the year ending December 31, 2024, to 47.2% in the year ending December 31, 2025, primarily due to our business restructuring focusing on high-quality and cash-generating growth, resulting in a deliberate reduction in low-profit margin pharmacy value-added solutions.